Canopy Growth (CGC) Net Income towards Common Stockholders Growth (1y) (2020 - 2025)
Canopy Growth (CGC) Net Income towards Common Stockholders Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 68.18% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.62% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2,405.06% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Canopy Growth | 276.52 Mn | 10.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -251.50% |
| Sep 30, 2024 | 101.81% |
| Jun 30, 2024 | 106.44% |
| Mar 31, 2024 | 103.93% |
| Dec 31, 2023 | 135.81% |
| Sep 30, 2023 | -57.16% |
| Jun 30, 2023 | 98.58% |
| Mar 31, 2023 | 89.20% |
| Dec 31, 2022 | 69.82% |
| Sep 30, 2022 | -546.24% |
| Jun 30, 2022 | -617.16% |
| Mar 31, 2022 | -366.13% |
| Dec 31, 2021 | 85.60% |
| Sep 30, 2021 | 82.09% |
| Jun 30, 2021 | 442.79% |
| Mar 31, 2021 | 91.98% |
| Dec 31, 2020 | -665.92% |
| Sep 30, 2020 | -139.41% |
| Jun 30, 2020 | 36.19% |
| Mar 31, 2020 | -1,674.85% |